Inhaled budesonide aerosols in treatment of childhood asthma.
Twenty-six children with chronic bronchial asthma, 19 boys and 7 girls, aged between 6 and 16 years with duration of asthma ranging from 1-12 years, were studied by a control, oral prednisolone 5 mg twice a day and inhaled budesonide 200 micrograms twice daily, each for 3 weeks. The clinical efficacy assessed daily by day and night symptom scores of cough, wheeze, sleep disturbance, limitation of activity, symptomatic inhaled terbutaline usage, daily morning and afternoon Peak Expiratory Flow Rate (PEFR), and weekly PEFR and Forced Expiratory Volume in 1 second (FEV1) in percent of predict, showed statistically significant improvement during the inhaled budesonide aerosol and oral prednisolone treatment periods in comparison with the control. No side effect was observed during any study periods.
Phanichyakarn
P
P
Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Wong
E C
EC
D000287:Administration, Topical; D000293:Adolescent; D000336:Aerosols; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy*; D019819:Budesonide; D002648:Child; D002908:Chronic Disease; D005260:Female; D005938:Glucocorticoids; D006801:Humans; D008297:Male; D008499:Medical Records; D010366:Peak Expiratory Flow Rate; D011239:Prednisolone / Q000627:therapeutic use; D011282:Pregnenediones / Q000008:administration & dosage / Q000627:therapeutic use*; D013785:Thailand
D000336:Aerosols; D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D011282:Pregnenediones; D019819:Budesonide; D011239:Prednisolone